(2) Marzook A, et al
Following rigorous quality control measures, which included the exclusion of duplicate entries, reports with incomplete demographic data (age or gender), and cases with missing temporal information, we retained 13,047 AE reports associated with concomitant GLP-1 receptor agonist and metformin therapy for final analysis
Phase 2 clinical trials of retatrutide, including the landmark studies published in the New England Journal of Medicine in 2023, primarily evaluated the drug's efficacy and safety in terms of weight reduction, cardiovascular markers, and gastrointestinal tolerability
[12] [13] This is particularly relevant for time-critical medications
Different medications have different tolerance windows for room temperature exposure
Curr Opin Mol Ther 12:790797 Onge EL, Miller SA (2010) Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes